Stomatitis News and Research

RSS

U.S. FDA approves first drug for patients with germline BRCA-mutated metastatic breast cancer

AstraZeneca and Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved LYNPARZA (olaparib) for use in patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting.

12 Jan 2018

FDA grants approval to first biosimilar for treatment of patients with breast, stomach cancers

The U.S. Food and Drug Administration today approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+).

4 Dec 2017

FDA approves first adjuvant treatment to reduce risk of kidney cancer recurrence

The U.S. Food and Drug Administration today approved Sutent (sunitinib malate) for the adjuvant treatment of adult patients who are at a high risk of kidney cancer (renal cell carcinoma) returning after a kidney has been removed (nephrectomy).

17 Nov 2017

Ebola vaccine that provides a year’s worth of protection developed

Liberia’s Ebola outbreak has yielded a successful trial of two vaccines against the deadly infection that could provide protection for up to a year and is also deemed to be safe.

12 Oct 2017

FDA approves drug to treat patients with newly diagnosed CD33-positive AML

The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML).

1 Sep 2017

Sanford Health launches solid tumor oncolytic virus clinical trial

Sanford Health is the first site in the United States to launch a clinical trial using a genetically-engineered virus that aims to destroy therapy-resistant tumors.

17 Aug 2017

FDA approves first extended adjuvant therapy to lower risk of breast cancer recurrence

The U.S. Food and Drug Administration today approved Nerlynx (neratinib) for the extended adjuvant treatment of early-stage, HER2-positive breast cancer.

18 Jul 2017

Phase 1 clinical studies reveal safety, tolerability of therapeutic vaccine in celiac disease patients

ImmusanT, Inc., a clinical-stage company developing Nexvax2, a therapeutic vaccine intended to protect against the effects of gluten exposure while maintaining a gluten-free diet in HLA-DQ2.5+ patients with celiac disease, today announced the publication of positive data from two Phase 1 clinical trials of Nexvax2 in celiac disease.

12 May 2017

Early blood test can predict vaccine immunogenicity

Within seven days of vaccination, a blood test early after vaccination can predict whether vaccines based on living, modified viruses have had the desired effect.

26 Apr 2017

Researcher aims to eliminate chemotherapy-resistant ovarian tumors using virus treatment

In some cases, the Lassa virus starts with a fever and general weakness, moving toward headache, muscle pain, possible facial swelling, deafness, and worse. About 15 percent of patients hospitalized with severe cases die.

20 Apr 2017

‘Geneva signature’ evaluates safety and immunogenicity of promising anti-Ebola virus vaccine

An international team based at Geneva University Hospitals and at the University of Geneva, Switzerland, has succeeded in defining a "signature" composed of a small number of inflammatory markers that can be monitored in order to understand how a promising anti-Ebola virus vaccine stimulates the immune system.

19 Apr 2017

Research sheds new light on reasons behind recurrent aphthous stomatitis

A burning pain sensation - and treatments that do not work. This is what daily life is like for many of those who suffer from recurrent aphthous stomatitis. Research from the Sahlgrenska Academy now sheds new light on the reasons behind this condition found in the mouth.

29 Mar 2017

Penn Vet researchers identify potential target to fight against Ebola

Viruses and their hosts are in a eternal game of one-upmanship. If a host cell evolves a way to stop a virus from spreading, the virus will look for a new path. And so on and so forth.

12 Jan 2017

Experimental Ebola vaccine offers high protection against deadly virus, reveals major trial

An experimental Ebola vaccine was highly protective against the deadly virus in a major trial in Guinea, according to results published today in The Lancet. The vaccine is the first to prevent infection from one of the most lethal known pathogens, and the findings add weight to early trial results published last year.

23 Dec 2016

Super-Resolution Imaging of Biological Specimens

In this interview, News Medical speaks to Dr. Manasa Gudheti of Bruker Nano Surfaces about biological specimens and how to acquire super-resolution images of them.

From Bruker Nano Surfaces and Metrology 27 Sep 2016

Novel Trojan Horse antibody strategy may target Ebola's Achilles' heel

In research published online today in Science, a team of scientists describe a new therapeutic strategy to target a hidden Achilles' heel shared by all known types of Ebola virus.

8 Sep 2016

Researchers develop new formulations for topical treatments of oral mucosal conditions

On June 24, 2016, at the 94th General Session & Exhibition of the International Association for Dental Research, researcher W. Peter Holbrook, University of Iceland, will present a study titled "Development of Drugs for Local Treatment of Oral Conditions." The IADR General Session is being held in conjunction with the 3rd Meeting of the IADR Asia Pacific Region and the 35th Annual Meeting of the IADR Korean Division.

24 Jun 2016

Positive effects of good nutrition linked to child's social behavior, development

Proper nutrition during childhood can positively affect a child's social behaviors and development.

11 May 2016

Bayer-new phase 3 liver cancer data

Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress.

4 May 2016

Ebola vaccine shows promise in clinical trials

"The results for tolerability, safety, and the immune response to the vaccine candidate are very promising," explains Prof Marylyn Addo. The antibodies which developed against the virus were still detectable after six months. Addo is convinced, "With this, a single vaccine could provide lasting protection against Ebola." The infectious disease specialist, who works for the German Center for Infection Research at the University Medical Center Hamburg Eppendorf in Hamburg, led the trial in Hamburg.